2-[3-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazol-4-yl]acetic acid

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 咪唑核糖核苷和核糖核苷酸
• 英文名称: 2-[3-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazol-4-yl]acetic acid
• 化学式: C₁₀H₁₄N₂O₆
• 分子量: 258.23
• InChiKey: XSDXFPMKRSXISO-XIWVQZPPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  125
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• [EN] USE OF HISTAMINE METABOLITES AS MARKERS FOR THE TREATMENT OF IBS WITH H1-R ANTAGONISTS<br/>[FR] UTILISATION DE MÉTABOLITES DE L'HISTAMINE COMME MARQUEURS POUR LE TRAITEMENT DU SYNDROME DU CÔLON IRRITABLE (IBS) AVEC DES ANTAGONISTES DU RÉCEPTEUR H1 (H1-R)
  申请人：UNIV LEUVEN KATH

  公开号：WO2017102640A1

  公开（公告）日：2017-06-22

  The invention relates to methods for determining whether treatment with an H1- receptor antagonist is likely to cure a visceral sensitivity disorder in a irritable bowel syndrome (IBS) patient or a functional dyspepsia patient comprising determining whether a body sample of said patient has increased levels of a histamine metabolite relative to levels in a normal tissue sample of a healthy individual, wherein an increase of a histamine metabolite is indicative for the effectivity of a treatment to be performed with said H1-receptor antagonist of said visceral sensitivity disorder.